319 related articles for article (PubMed ID: 16741247)
1. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
[TBL] [Abstract][Full Text] [Related]
3. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
[TBL] [Abstract][Full Text] [Related]
4. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
5. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.
Jekarl DW; Han SB; Kim M; Lim J; Oh EJ; Kim Y; Kim HJ; Min WS; Han K
Korean J Hematol; 2010 Mar; 45(1):46-50. PubMed ID: 21120162
[TBL] [Abstract][Full Text] [Related]
6. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
7. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
8. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
[TBL] [Abstract][Full Text] [Related]
9. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
[No Abstract] [Full Text] [Related]
10. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
11. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
[TBL] [Abstract][Full Text] [Related]
12. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
[No Abstract] [Full Text] [Related]
13. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
[No Abstract] [Full Text] [Related]
14. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Steensma DP; Dewald GW; Lasho TL; Powell HL; McClure RF; Levine RL; Gilliland DG; Tefferi A
Blood; 2005 Aug; 106(4):1207-9. PubMed ID: 15860661
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Malcovati L; Della Porta MG; Pietra D; Boveri E; Pellagatti A; Gallì A; Travaglino E; Brisci A; Rumi E; Passamonti F; Invernizzi R; Cremonesi L; Boultwood J; Wainscoat JS; Hellström-Lindberg E; Cazzola M
Blood; 2009 Oct; 114(17):3538-45. PubMed ID: 19692701
[TBL] [Abstract][Full Text] [Related]
16. MDS/MPN-RS-T justified inclusion as a unique disease entity?
Montalban-Bravo G; Garcia-Manero G
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
[TBL] [Abstract][Full Text] [Related]
17. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
Campbell PJ; Scott LM; Baxter EJ; Bench AJ; Green AR; Erber WN
Methods Mol Med; 2006; 125():253-64. PubMed ID: 16502590
[TBL] [Abstract][Full Text] [Related]
18. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
19. Refractory anemia with ring sideroblasts.
Malcovati L; Cazzola M
Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
[TBL] [Abstract][Full Text] [Related]
20. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
Yoshimi A; Abdel-Wahab O
Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
